Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1859
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4877    
    Printed206    
    Emailed3    
    PDF Downloaded561    
    Comments [Add]    
    Cited by others 14    

Recommend this journal

 

 SYMPOSIUM
Year : 2010  |  Volume : 47  |  Issue : 3  |  Page : 248-259

Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents


1 Head and Neck Unit, The Royal Marsden Hospital, London and Surrey; The Institute of Cancer Research, 237 Fulham Road, London, United Kingdom
2 Head and Neck Unit, The Royal Marsden Hospital, London and Surrey, United Kingdom

Correspondence Address:
K J Harrington
Head and Neck Unit, The Royal Marsden Hospital, London and Surrey; The Institute of Cancer Research, 237 Fulham Road, London
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.64711

Rights and Permissions

Despite significant improvements in the treatment and outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) that have resulted from technological advances in radiation delivery and the use of cytotoxic chemotherapy, there is still a pressing need for novel therapies. In the last two decades, our understanding of the molecular biological basis of cancer has provided us with a new framework for developing specific targeted therapies. It is likely that the next wave of developments will include active small molecule inhibitors of epidermal growth factor receptor (EGFR) (and other members of the c-erbB family of receptors), antiangiogenic agents, and drugs that can increase proapoptotic signaling in cancer cells. As with cetuximab, it is most likely that these new agents will first find a niche in the context of combination regimens with standard anticancer therapeutics.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow